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Abstract
Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has evolved
in recent years as the leading global cause of chronic liver damage. The main
obstacle to better disease management pertains to the lack of approved
pharmacological interventions for the treatment of nonalcoholic steatohepatitis
(NASH) and NASH-fibrosis-the severe histological forms. Over the past decade,
tremendous advances have been made in NAFLD research, resulting in the
discovery of disease mechanisms and novel therapeutic targets. Hence, a large
number of pharmacological agents are currently being tested for safety and
efficacy. These drugs are in the initial pharmacological phases (phase 1 and 2),
which involve testing tolerability, therapeutic action, and pharmacological issues.
It is thus reasonable to assume that the next generation of NASH drugs will not
be available for clinical use for foreseeable future. The expected delay can be
mitigated by drug repurposing or repositioning, which essentially relies on
identifying and developing new uses for existing drugs. Here, we propose a drug
candidate selection method based on the integration of molecular pathways of
disease pathogenesis into network analysis tools that use OMICs data as well as
multiples sources, including text mining from the medical literature.
Key words: Drug discovery; Drug repositioning; Fibrosis; Genetics; Treatment; Systems
biology
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Core tip: As a proof-of-concept of the advantages that can be yielded by applying multi-
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of nonalcoholic steatohepatitis (NASH) we selected the Kyoto Encyclopedia of Genes
and Genomes (KEGG) pathway map of nonalcoholic fatty liver disease (NAFLD),
which illustrates a stage-dependent progression of the disease. After generating a
protein−chemical interaction network, we predicted remarkable examples of potential
drug repurposing for the treatment of NASH based on the NAFLD-KEGG connectivity
map.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is a complex disorder that has emerged as
the leading global cause of chronic liver damage in recent years[1]. The disease course
progresses through highly dynamic histological stages, ranging from simple steatosis
or nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), NASH-
fibrosis and cirrhosis[1,2]. NASH-fibrosis and its complications, including cirrhosis and
hepatocellular carcinoma, not only significantly reduce life expectancy by increasing
liver-related mortality[3]  but also represent a challenge for the healthcare system
because  much  of  the  affected  population  is  also  affected  by  NAFLD-associated
comorbidities,  including  obesity,  type  2  diabetes  (T2D),  and  cardiovascular
disease[1,4-6]. Absence of reliable noninvasive biomarkers that allow identification of
patients at a high risk of fibrosis and /or disease progression is one of the obstacles
facing disease management[7,8].  Similarly,  while  a  large number of  drugs against
NASH  are  currently  being  tested  for  efficacy  and  safety,  no  pharmacological
interventions are presently approved for treating NASH[2,5,9,10].
Information  retrieved  from  public  domain  data  sources  and  clinical
ClinicalTrials.gov (updated December 2018), a resource provided by the U.S. National
Library of Medicine, indicates that approximately 47 different drugs that target NASH
and NASH-fibrosis are currently being tested in different pharmacological stages,
including 188 drugs in phase 1 and 162 in phase 2 studies (Figure 1). A significant
proportion of these drugs are small molecules or proteins that either antagonize or act
as exogenous agonists of one or more targets of interest; the 47 aforementioned NASH
drugs  are  in  fact  predicted  to  be  linked  to  151  molecular  targets  (Figure  1).
Considering that a large majority of these drugs are in the earliest pharmacological
phases  that  involve testing tolerability,  therapeutic  action,  and pharmacological
issues, it is reasonable to conclude that there will be a significant time lag before the
next generation of NASH drugs is available for clinical use.
One potential solution to this expected delay is drug repurposing or repositioning,
which  relies  on  identifying  and developing  new uses  for  existing  drugs[11].  The
advantage of drug repurposing is not limited to the fact that drugs selected for a novel
indication  have  already  passed  the  time-consuming  pharmacokinetics,
pharmacodynamics, and toxicity profiling evaluation, but are also already approved
by  major  regulatory  agencies,  including  the  United  States  Food  and  Drug
Administration and/or the European Medicines Agency.
Drug repurposing can be addressed by different approaches. Most common ones
involve the selection of drug candidate/s based on known targets involved in the
pathogenesis of the disease of interest. More recently, system biology strategies based
on a broad search into genomic resources,  as well  as large-scale gene expression
libraries, have been proposed as an attractive and innovative solution, particularly for
the treatment of complex diseases like NAFLD that shares disease mechanisms with
diseases  of  the  metabolic  syndrome[12-14].  Hence,  we  propose  a  drug  candidate
selection  method  based  on  the  integration  of  molecular  pathways  of  disease
pathogenesis into network analysis tools that use OMICs data as well as multiples
sources, including text mining from pertinent medical literature.
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Figure 1
Figure 1  Clinical trials for the treatment of nonalcoholic steatohepatitis. A and B: Figure highlights 47 drugs that are currently under investigation for the
treatment of nonalcoholic steatohepatitis in different pharmacological phases (from phase 1 to phase 4): Information on clinical trial status (recruitment status) as well
as prediction of potential associated targets were retrieved from the Target Validation Platform available at https://www.targetvalidation.org; C: Drugs listed in the most
advanced pharmacological phase updated December 2018 concerning to privately and publicly funded clinical studies. Not yet recruiting: The study has not started
recruiting participants; Recruiting: The study is currently recruiting participants; Active, not recruiting: The study is ongoing, and participants are receiving an
intervention or being examined, but potential participants are not currently being recruited or enrolled; Terminated: The study has stopped early and will not start
again; participants are no longer being examined or treated; Completed: The study has ended normally, and participants are no longer being examined or treated (that
is, the last participant's last visit has occurred); Withdrawn: The study stopped early, before enrolling its first participant; Unknown: A study on ClinicalTrials.gov whose
last known status was recruiting; not yet recruiting; or active, not recruiting but that has passed its completion date, and the status has not been last verified within the
past 2 years).
DRUG REPURPOSING FOR THE TREATMENT OF NASH
BASED ON THE NAFLD-KEGG CONNECTIVITY MAP
As  a  proof-of-concept  of  the  advantages  of  using  multi-omics  systems-based
approaches for the analysis of potential NASH treatment candidates, we selected the
Kyoto  Encyclopedia  of  Genes  and  Genomes  (KEGG)  pathway  map  of  NAFLD
(pathway ID:  hsa04932),  which  illustrates  a  stage-dependent  progression  of  the
disease (Figure 2). This pathway is composed of 149 genes/proteins involved not only
in the progression of NAFL to NASH and to cirrhosis, but also genes/proteins shared
with obesity and T2D (Table 1).  Significant disease-related pathogenic processes,
including de novo fatty acid biosynthesis, lipid peroxidation, endoplasmic reticulum
stress and mitochondrial dysfunction[15-17], as well as apoptosis and cell death related
mechanisms are represented in the NAFLD-KEGG pathway (Figure 2).  Thus, we
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generated  a  protein−chemical  interaction  network  by  mapping  the  significant
genes/proteins that  are represented in the pathway to chemicals/drugs that  are
annotated in  the  Comparative  Toxicogenomics  Database.  The  149  genes  (seeds)
yielded by our analysis were then mapped to the corresponding molecular interaction
database; this procedure produced an extensive network comprising of approximately
2000  nodes.  One  of  the  largest  subnetworks  included  3212  smaller  nodes  (that
represent the number of gene/protein–chemical interactions in this subnetwork), with
13314 interactions among node members. For simplicity, we manually curated some
chemical−drug  interactions  focusing  specifically  on  certain  genes/proteins  of
potential interest,  including members of the caspase family (CASP3 and CASP7),
interleukins (IL1A, IL1B, and IL6), tumor necrosis factor α (TNFα), nuclear factor
kappa B subunit 1 (NFKB1) and inhibitor of nuclear factor kappa B kinase subunit
beta,  Jun  proto-oncogene  (JUN),  transcription  factor  subunit,  and  AKT
serine/threonine kinase 1 (Figure 3). Remarkably, several drugs were predicted to
have a significant interaction with the highlighted targets. For example, minocycline
that is  a broad spectrum long-acting derivative of the antibiotic tetracycline was
mapped in the pathway of caspases, whereas IL1B (Figure 3) or pomalidomide that is
a  derivative  of  thalidomide  with  immuno-modulating,  antiangiogenic  and
antineoplastic activities was mapped in the network of TNF, NFKB1, and interleukins
(Figure 3).
Additional  targets  predicted  in  the  minoclycline  interaction  network  are
arachidonate 5-lipoxygenase (which is involved in the synthesis of leukotrienes from
arachidonic acid), cytochrome C (a central component of the electron transport chain
in  mitochondria),  matrix  metallopeptidase  9  (involved  in  the  breakdown  of
extracellular  matrix),  vascular  endothelial  growth  factor  A  (which  induces
proliferation  and  migration  of  vascular  endothelial  cells,  particularly  during
pathological angiogenesis) and Poly(ADP-ribose) polymerase 1 (which is involved in
the regulation of a myriad of cellular processes, such as differentiation, proliferation,
and tumor transformation, as well as in the regulation of the molecular events implicit
in the cell recovery from DNA damage). Further two candidate targets predicted in
the  network  of  pomalidomide  are  prostaglandin-endoperoxide  synthase  2  (also
known as cyclooxygenase, which is the key enzyme in prostaglandin biosynthesis)
and CRBN (a calcium channel membrane protein, thought to play a role in brain
development).
Additional examples of drugs that could be potentially tested for the treatment of
NASH based on the concept of drug repositioning are illustrated in Figure 3. Drugs in
the  category  of  angiotensin  II  receptor  type  1  (AGTR1)  antagonists  that  were
predicted  in  the  network  of  JUN,  for  instance  irbersartan-a  nonpeptide  AGTR1
antagonist with antihypertensive activity-might indeed be regarded as an indication
expansion rather than drug repositioning because, as mentioned above, NAFLD and
components of the Metabolic Syndrome, including arterial hypertension, present
shared disease mechanisms (12-14). Therefore, given the pleiotropic effects of AGTR1
blockers[18] it is plausible to suggest that drugs in this pharmacological group-sartans-
would synergize or potentiate the benefits of blocking the renin angiotensin system in
the liver[19-22].  Remarkably, the pharmacological properties and toxicity profiles of
some of the drugs presently undergoing NASH clinical trials are already known, such
as atorvastatin, ezetimibe, fenofribrate, losartan, and pioglotazone, just to mention a
few (Figure 1).
PLEIOTROPY: CHALLENGES AND OPPORTUNITIES FOR
THE TREATMENT OF NASH
It  is  also  important  to  acknowledge  the  possibility  that  some  of  the  novel
pharmacotherapy  options  for  the  treatment  of  NASH might  eventually  present
pleiotropic effect/s. This point represents the paradox of a drug covering multiple
pathways and cell types, which could be either harmful or beneficial for patients.
Remarkable examples of the advantages of pleiotropic effects of pharmacological
targets for the treatment of complex traits are, as already mentioned, agents that
modulate or interfere with the rennin−angiotensin system, which not only reduce
cardiovascular risk but also improve systemic inflammation, oxidative stress, and
even present anti-fibrogenic properties in the liver. Similar effects have also been
demonstrated for statins[23,24].
When focusing on the new generation of NASH targets, obeticholic acid (OCA), a
synthetically-modified bile acid (a dihydroxy-5beta-cholanic acid), is a remarkable
example of the potential systemic effects of a drug targeting nuclear receptors. OCA
exhibits  a  potent  agonist  effect  on the farnesoid X nuclear  receptor  (FXR).  More
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Table 1  Non-alcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway
(hsa04932)
Gene symbol; description
IL6; interleukin 6
IL6R; interleukin 6 receptor
SOCS3; suppressor of cytokine signaling 3
TNF; tumor necrosis factor
TNFRSF1A; TNF receptor superfamily member 1A
NFKB1; nuclear factor kappa B subunit 1
RELA; RELA proto-oncogene, NF-kB subunit
INS; insulin
INSR; insulin receptor
IRS1; insulin receptor substrate 1
IRS2; insulin receptor substrate 2
PIK3CA; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha
PIK3CD; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta
PIK3CB; phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta
PIK3R1; phosphoinositide-3-kinase regulatory subunit 1
PIK3R2; phosphoinositide-3-kinase regulatory subunit 2
PIK3R3; phosphoinositide-3-kinase regulatory subunit 3
AKT1; AKT serine/threonine kinase 1
AKT2; AKT serine/threonine kinase 2
AKT3; AKT serine/threonine kinase 3
GSK3A; glycogen synthase kinase 3 alpha
GSK3B; glycogen synthase kinase 3 beta
NR1H3; nuclear receptor subfamily 1 group H member 3
RXRA; retinoid X receptor alpha
SREBF1; sterol regulatory element binding transcription factor 1
MLX; MLX, MAX dimerization protein
MLXIP; MLX interacting protein
MLXIPL; MLX interacting protein like
PKLR; pyruvate kinase L/R
LEP; leptin
LEPR; leptin receptor
ADIPOQ; adiponectin, C1Q and collagen domain containing
ADIPOR1; adiponectin receptor 1
ADIPOR2; adiponectin receptor 2
PRKAA1; protein kinase AMP-activated catalytic subunit alpha 1
PRKAA2; protein kinase AMP-activated catalytic subunit alpha 2
PRKAB1; protein kinase AMP-activated non-catalytic subunit beta 1
PRKAB2; protein kinase AMP-activated non-catalytic subunit beta 2
PRKAG1; protein kinase AMP-activated non-catalytic subunit gamma 1
PRKAG3; protein kinase AMP-activated non-catalytic subunit gamma 3
PRKAG2; protein kinase AMP-activated non-catalytic subunit gamma 2
PPARA; peroxisome proliferator activated receptor alpha
CDC42; cell division cycle 42
RAC1; Rac family small GTPase 1
MAP3K11; mitogen-activated protein kinase kinase kinase 11
MAPK8; mitogen-activated protein kinase 8
MAPK10; mitogen-activated protein kinase 10
MAPK9; mitogen-activated protein kinase 9
ITCH; itchy E3 ubiquitin protein ligase
ERN1; endoplasmic reticulum to nucleus signaling 1
TRAF2; TNF receptor associated factor 2
MAP3K5; mitogen-activated protein kinase kinase kinase 5
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JUN; Jun proto-oncogene, AP-1 transcription factor subunit
IL1A; interleukin 1 alpha
IL1B; interleukin 1 beta
IKBKB; inhibitor of nuclear factor kappa B kinase subunit beta
XBP1; X-box binding protein 1
CEBPA; CCAAT enhancer binding protein alpha
CYP2E1; cytochrome P450 family 2 subfamily E member 1
FASLG; Fas ligand
CXCL8; C-X-C motif chemokine ligand 8
TGFB1; transforming growth factor beta 1
EIF2AK3; eukaryotic translation initiation factor 2 alpha kinase 3
EIF2S1; eukaryotic translation initiation factor 2 subunit alpha
ATF4; activating transcription factor 4
DDIT3; DNA damage inducible transcript 3
BCL2L11; BCL2 like 11
BAX; BCL2 associated X, apoptosis regulator
FAS; Fas cell surface death receptor
CASP8; caspase 8
BID; BH3 interacting domain death agonist
CYCS; cytochrome c, somatic
CASP3; caspase 3
CASP7; caspase 7
NDUFV1-3; NADH:ubiquinone oxidoreductase core subunit V1 –V3
NDUFA1-3; NADH:ubiquinone oxidoreductase subunit A1-3
NDUFA4; NDUFA4, mitochondrial complex associated
NDUFA4L2; NDUFA4, mitochondrial complex associated like 2
NDUFA5-13; NADH:ubiquinone oxidoreductase subunit A5-A13
NDUFAB1; NADH:ubiquinone oxidoreductase subunit AB1
NDUFB1-11; NADH:ubiquinone oxidoreductase subunit B1-B11
NDUFS1-S8; NADH:ubiquinone oxidoreductase core subunit S1 –S8
NDUFC1; NADH:ubiquinone oxidoreductase subunit C1
NDUFC2; NADH:ubiquinone oxidoreductase subunit C2
NDUFC2-KCTD14; NDUFC2-KCTD14 readthrough
SDHA; succinate dehydrogenase complex flavoprotein subunit A
SDHB; succinate dehydrogenase complex iron sulfur subunit B
SDHC; succinate dehydrogenase complex subunit C
SDHD; succinate dehydrogenase complex subunit D
UQCRFS1; ubiquinol-cytochrome c reductase, Rieske iron-sulfur polypeptide 1
CYTB; cytochrome b
CYC1; cytochrome c1
UQCRC1; ubiquinol-cytochrome c reductase core protein 1
UQCRC2; ubiquinol-cytochrome c reductase core protein 2
UQCRH; ubiquinol-cytochrome c reductase hinge protein
UQCRHL; ubiquinol-cytochrome c reductase hinge protein like
UQCRB; ubiquinol-cytochrome c reductase binding protein
UQCRQ; ubiquinol-cytochrome c reductase complex III subunit VII
UQCR10; ubiquinol-cytochrome c reductase, complex III subunit X
UQCR11; ubiquinol-cytochrome c reductase, complex III subunit XI
COX3; cytochrome c oxidase III
COX1; cytochrome c oxidase subunit I
COX2; cytochrome c oxidase subunit II
COX4I2; cytochrome c oxidase subunit 4I2
COX4I1; cytochrome c oxidase subunit 4I1
COX5A; cytochrome c oxidase subunit 5A
COX5B; cytochrome c oxidase subunit 5B
COX6A1; cytochrome c oxidase subunit 6A1
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COX6A2; cytochrome c oxidase subunit 6A2
COX6B1; cytochrome c oxidase subunit 6B1
COX6B2; cytochrome c oxidase subunit 6B2
COX6C; cytochrome c oxidase subunit 6C
COX7A1; cytochrome c oxidase subunit 7A1
COX7A2; cytochrome c oxidase subunit 7A2
COX7A2L; cytochrome c oxidase subunit 7A2 like
COX7B; cytochrome c oxidase subunit 7B
COX7B2; cytochrome c oxidase subunit 7B2
COX7C; cytochrome c oxidase subunit 7C
COX8C; cytochrome c oxidase subunit 8C
COX8A; cytochrome c oxidase subunit 8A
https://www.genome.jp/kegg-bin/show_pathway? hsa04932.
importantly, its target-FXR (formally Nuclear hormone receptor subfamily 1 group H
member  4,  NR1H4,  also  known  as  BAR)  is  predicted  to  be  involved  in  the
pathogenesis of multiple phenotypes that practically cover the full range of human
diseases and traits (Figure 4). It is well known that OCA is currently used to treat not
only  NASH  but  other  chronic  liver  diseases  as  well,  including  primary  biliary
cholangitis[25].  However,  there  are  at  least  65  registered clinical  trials  in  various
pharmacological phases for ~50 different diseases (Figure 4).
Based on this evidence, one may presume that the pleiotropic effects, and thus the
clinical consequences, of the novel NASH drugs that are predicted to concurrently
modulate a broad range of molecular pathways could be surprisingly extensive and
therefore largely beneficial  for treating multiple phenotypes. However,  potential
pleiotropic effects of the novel anti-NASH drugs could produce undesirable effects
that we need to understand in order to anticipate their management. Some of these
potential pleiotropic effects are indeed related to the primary biological and molecular
network associated with the drug target itself. To illustrate the importance of this
issue,  we  randomly  selected  five  molecular  targets  (MAP3K5  or  ASK1,  FXR,
PPARα/δ, THRβ, and MPC1) against which five drugs are currently being tested in
patients  with  NASH  (selonsertib [ 2 6 ] ,  OCA [ 2 7 ] ,  elafibranor [ 2 8 ] ,  MGL-3196
(https://clinicaltrials.gov/ct2/show/NCT02912260),  and  MSDC-0602K [ 2 9 ]
https://clinicaltrials.gov/ct2/show/NCT02784444). Next, we explored the potential
pleiotropic  effect/s  of  modulating  these  targets  in  humans  by  searching  for
associations  of  genetic  variants  in  the  aforementioned  targets  with  different
phenotypes and traits, known as PheWAS (Phenome-wide association studies). We
specifically  retrieved publically  available  information  from the  United  Kindom
Biobank that explored genetic variations in 452264 United Kindom Biobank White
British individuals (http://geneatlas.roslin.ed.ac.uk/)[30].
As shown in Figure 5 and Table 2, MAP3K5/ASK1, FXR, PPARα/δ, THRβ, and MPC1
variants are involved in multiple pleiotropic effects, including modulation of blood
cell  count,  body  mass  index,  and  general  body  adiposity,  along  with  complex
systemic  disorders,  such  as  asthma,  acute  pancreatitis,  migraine,  intestinal
malabsortium, thyroid disease, and malignant neoplasm. Hence, understanding the
pleiotropic effects of the novel NASH drugs is the key to optimizing their use as well
as preventing emergent-yet poorly understood-undesirable systemic complications
that could potentially jeopardize their short- or long-term use.
CONCLUSION
We provide new strategies and approaches by which known drugs can be repurposed
for the treatment of NASH. Although we explored and mapped NAFLD-chemical
interaction networks, it will be necessary to perform clinical trials not only to assess
therapeutic response and optimize dosage and delivery routes, but also to explore the
possibility that new uses of existing (old) drugs could act on novel or unanticipated
targets. The presence of potential “off target”-pleiotropic-effects raises the mandatory
necessity  of  pharmacological  optimization,  including  the  assessment  of  drug
interactions and adjustment according to liver function tests.
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Table 2  Associations between variants in locus that are targets of novel drugs for the treatment of nonalcoholic steatohepatitis and
multiple traits from individuals of the United Kindom Biobank
Trait Variant Position -log10(p-value)
NR1H4 (FXR) Farnesoid X-Activated Receptor
K85 Acute pancreatitis rs76372051 100945711 6.963890333
Immature reticulocyte fraction rs35712 100971355 5.607954097
Impedance of arm (right) rs1409791 100851307 5.152661824
Impedance of whole body rs1409791 100851307 4.772216099
migraine rs12579460 100966714 4.639293011
high cholesterol rs7967468 100853792 4.543497322
N30-N39 Other diseases of urinary system rs79306023 100938470 4.420628035
H81 Disorders of vestibular function rs140644635 100923359 4.069764347
PPARδ (Peroxisome Proliferator Activated Receptor Delta)
Whole body fat-free mass rs36018387 35386872 59.74853212
Hip circumference rs36018387 35386872 49.20670564
Whole body fat mass rs36018387 35386872 37.00113934
Body fat percentage rs36018387 35386872 20.45328464
Monocyte percentage rs9469982 35267548 45.86340625
Platelet crit rs33959228 35259397 21.6726615
White blood cell (leukocyte) count rs9380500 35266231 21.54556677
Platelet count rs9658111 35364534 17.88276186
Neutrophill count rs9380500 35266231 17.11253462
Eosinophill percentage rs2395625 35405461 15.34904201
Lymphocyte percentage rs9658079 35327577 9.741626151
asthma rs1557568 35260530 9.184130164
K90 Intestinal malabsorption rs7771474 35320447 11.86097145
MPC1 (Mitochondrial Pyruvate Carrier 1)
Mean platelet (thrombocyte) volume rs10946160 166757818 7.378512135
Platelet count rs3728 166778679 5.285527735
Red blood cell (erythrocyte) count rs6916128 166759313 4.825911105
M31 Other necrotising vasculopathies rs7449594 166774429 4.699926505
dyspepsia / indigestion rs6909951 166758198 4.594790286
MAP3K5 (ASK-1) (Mitogen-Activated Protein Kinase Kinase Kinase 5)
Mean platelet (thrombocyte) volume rs6924387 137082948 14.48853109
Eosinophill count rs932589 137083138 13.39556873
Lymphocyte percentage rs6924387 137082948 10.84396601
Neutrophill count rs6924387 137082948 10.59715422
Platelet count rs9321570 137095679 9.792150289
White blood cell (leukocyte) count rs6924387 137082948 9.574319083
Eosinophill percentage rs932589 137083138 9.344890391
Monocyte count rs9385775 137144920 9.1157769
Mean reticulocyte volume rs9385775 137144920 8.817927896
Platelet distribution width rs6924387 137082948 8.001963098
THRβ (Thyroid Hormone Receptor Beta)
Mean corpuscular volume rs869785 24347800 152.2743497
Mean corpuscular haemoglobin rs869784 24348008 143.9371173
Red blood cell (erythrocyte) count rs869785 24347800 61.9076303
Mean reticulocyte volume rs869784 24348008 43.97976306
Reticulocyte count rs1505307 24343330 16.57632823
Immature reticulocyte fraction rs869784 24348008 15.67096843
Monocyte count rs12485694 24346109 11.11788547
Lymphocyte count rs13096529 24232035 10.58643203
Red blood cell (erythrocyte) distribution width rs2167115 24339734 10.44361306
C56 Malignant neoplasm of ovary rs189397255 24389732 12.2277003
Trunk fat-free mass rs13100197 24491484 8.731024419
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Trunk predicted mass rs13100197 24491484 8.614769205
Leg fat percentage (left) rs1349265 24159387 8.323233252
The associations have been computed using 452264 United Kindom Biobank White British individuals. http://geneatlas.roslin.ed.ac.uk/.
Figure 2
Figure 2  Nonalcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway and mechanisms of disease pathogenesis. Pathway was
retrieved from https://www.genome.jp/dbget-bin/www_bget?pathway+hsa04932; figure was modified to highlight key molecular processes. This map shows a stage-
dependent progression of nonalcoholic fatty liver disease (NAFLD). In the first stage of NAFLD, pathway highlights excess lipid accumulation associated with the
induction of insulin resistance, which leads to a defect in insulin suppression of free fatty acids (FAAs) disposal. In addition, two transcription factors, SREBP-1c and
PPARα, activate key enzymes of lipogenesis and increase the synthesis of FAAs in liver. In the second stage, pathway is presented as a consequence of the
progression to nonalcoholic steatohepatitis (NASH); the production of reactive oxygen species is enhanced due to oxidation stress through mitochondrial beta-
oxidation of fatty acids and endoplasmic reticulum (ER) stress, leading to lipid peroxidation. The lipid peroxidation can further cause the production of cytokines [Fas
ligand, tumor necrosis factor α (TNF-α), IL-8 and transforming growth factor], promoting cell death, inflammation and fibrosis. The activation of JNK, which is induced
by ER stress, TNF-α and FAAs, is also associated with NAFLD progression. Increased JNK promotes cytokine production and initiation of hepatocellular carcinoma.
Major organelles involved in the pathogenesis of NASH are also highlighted in the NAFLD-pathway, including mitochondria and mitochondrial dysfunction. In the
figure, molecular targets that were further selected to explore protein-chemical interactions are highlighted by red squares. NAFLD: Nonalcoholic fatty liver disease;
NASH: Nonalcoholic steatohepatitis; ER: Endoplasmic reticulum; HCC: Hepatocellular carcinoma; NAFL: Nonalcoholic fatty liver; FAAs: Free fatty acids; TNFα: tumor
necrosis factor α.
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Figure 3
Figure 3  Protein-chemical interactions and potential repurposing drugs to target nonalcoholic steatohepatitis. We generated a protein-chemical interaction
network by mapping the significant genes/proteins that are represented in the nonalcoholic fatty liver disease-Kyoto Encyclopedia of Genes and Genomes pathway to
chemicals/drugs that are annotated in the Comparative Toxicogenomics Database. The 149 genes (seeds) from our analysis were mapped to the corresponding
molecular interaction database; full list of seed genes is listed in Table 1. This analysis generated a huge network composed of approximately 2000 nodes. Current
figure shows chemical-drug-interactions specifically focused on selected genes/proteins of potential interest, including members of the caspase family (CASP3 and
CASP7), interleukins (IL1B, IL1A, and IL6), tumor necrosis factor α (TNF-α), NFKB1 (Nuclear factor kappa B subunit 1) and IKBKB (inhibitor of nuclear factor kappa B
kinase subunit beta), JUN (Jun proto-oncogene, AP-1 transcription factor subunit), AKT1 (AKT serine/threonine kinase 1). In green charts we summarized information
on current use and known action of selected drugs. Interaction network was predicted by the Networkanalyst resource available at
https://www.networkanalyst.ca/faces/home.xhtml. The network is shown as a Cytoscape graph.
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Figure 4
Figure 4  Farnesoid X nuclear receptor (nuclear hormone receptor subfamily 1 group H member 4): Analysis of pleiotropy. A: Graph shows all predicted
diseases associated with farnesoid X nuclear receptor; B: Clinical trials of drugs that target farnesoid X nuclear receptor. Predictions were explored in The Open
Targets Platform that allows prioritisation of drug targets based on the strength of their association with a disease (https://www.targetvalidation.org/); C: Evidence
curated from ClinicalTrials.gov, a database of privately and publicly funded clinical studies conducted around the world. https://clinicaltrials.gov/. Diseases are
presented as bubbles grouped into therapeutic areas using their Experimental Factor Ontology relationships. The size and shade of the color of each bubble is
proportional to the strength of association between the disease and farnesoid X nuclear receptor. The concept of a target-disease association is based on the analysis
of several resources, including genetic associations (GWAS Catalog, UniProt, European Variation Archive, Gene2Phenotype), somatic mutations (Cancer Gene
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Census, European Variation Archive somatic, IntOGen), RNA expression (expression atlas), drugs (ChEMBL), affected pathways (Reactome), animal models
(PhenoDigm) and text mining (Europe PMC). The platform is available at https://www.targetvalidation.org. Data last updated December 2018.
Figure 5
Figure 5  The complexity of molecular targets and novel nonalcoholic steatohepatitis drugs: Pleiotropy assessed in the PheWAS United Kindom Biobank.
Figure shows associations between gene variants in five nonalcoholic steatohepatitis-related molecular targets (MAP3K5/ASK1, FXR, PPARα/δ, THRβ, and MPC1)
with different traits and phenotypes in the UK-PheWAS (Phenome-wide association study). Information regarding single nucleotide polymorphisms and associations
were retrieved from the United Kindom Biobank (http://geneatlas.roslin.ed.ac.uk/).
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